Recently, atezolizumab and bevacizumab (Atez/Bev), which is a combination therapy of anti‐programmed death ligand‐1 (PD‐L1) and anti‐vascular endothelial growth factor (VEGF), was introduced as the first immune‐combined therapy for patients with HCC and showed advantages over sorafenib in terms of the overall and progression‐free survival.13 This evidence concerns the gene VEGFA and hepatocellular carcinoma.